Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | PLTP | P55058 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681332 | 0.94 | ABCB1 (0.38) | MAPK1ABCB1CDC7ALDH1A1HPGD | |
| SCHEMBL19206747 | 0.89 | DHFR (0.37) | LMNAGPR84CDC7ALDH1A1HPGD | |
| SCHEMBL954434 | 0.89 | ABCB1 (0.41) | ABCB1CDC7ALDH1A1HPGDADORA2A | |
| SCHEMBL64690 | 0.88 | ABCB1 (0.42) | ABCB1CDC7ALDH1A1HPGDADORA2A | |
| SCHEMBL12293879 | 0.88 | ABCB1 (0.42) | ABCB1CDC7ALDH1A1HPGDADORA2A | |
| SCHEMBL20841755 | 0.87 | GPR84 (0.42) | GPR84ABCB1ALDH1A1MAPTHPGD | |
| SCHEMBL10196893 | 0.87 | ABCB1 (0.39) | LMNAABCB1CDC7ALDH1A1MAPT | |
| SCHEMBL20841749 | 0.87 | ABCB1 (0.39) | LMNAABCB1CDC7ALDH1A1MAPT | |
| SCHEMBL5555331 | 0.87 | PDE4A (0.40) | LMNAMAPK1CDC7ALDH1A1HPGD | |
| SCHEMBL29887519 | 0.86 | CDC7 (0.43) | ABCB1CDC7ALDH1A1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORP (US) | 2026-01-29 | — | — | US | disclosed |
| US-12435354-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12215375-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240158831-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2024-05-16 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2022-11-03 | — | — | US | disclosed |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2022-11-03 | — | — | US | disclosed |
| US-20200399676-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2020-12-24 | — | — | US | disclosed |
| EP-2635582-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | Promega Corporation (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| WO-2012061529-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061529-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061530-A2 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | RNGTT, UPF1, NSUN2 | LMNA 1686/4885MAPK1 3051/4885GPR84 2909/4885 |
| US-12435354-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | LMNA 1382/4885MAPK1 2716/4885GPR84 2429/4885 |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | LMNA 1382/4885MAPK1 2716/4885GPR84 2429/4885 |
| US-20240158831-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | LMNA 1382/4885MAPK1 2716/4885GPR84 2429/4885 |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | LMNA 1382/4885MAPK1 2716/4885GPR84 2429/4885 |
| US-12215375-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | LMNA 1382/4885MAPK1 2716/4885GPR84 2429/4885 |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, VIP, PREP | LMNA 672/4885MAPK1 3915/4885GPR84 4306/4885 |
| US-20200399676-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | LMNA 1382/4885MAPK1 2716/4885GPR84 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.